SeaStar Medical Reports Positive Pediatric AKI Data, Highlights Immunomodulatory Mechanism
Event summary
- SeaStar Medical presented new data from the QUELIMMUNE SAVE Registry at AKI & CRRT 2026, showing no device-related adverse events and 69% survival rates in pediatric AKI patients.
- In vitro analysis demonstrated the SCD therapy modulates immune response, shifting monocytes to an anti-inflammatory, reparative phenotype.
- Company hosted an industry symposium with leading experts in pediatric AKI treatment, reinforcing its leadership in the community.
- QUELIMMUNE therapy, approved in 2024, has shown a 77% survival rate in clinical trials, significantly reducing mortality in pediatric AKI patients.
The big picture
SeaStar Medical is positioning itself as a leader in the treatment of pediatric AKI, a condition with historically high mortality rates. The company's focus on immunomodulation through its SCD therapy sets it apart in a market where traditional treatments often fall short. With the NEUTRALIZE-AKI pivotal trial underway for adult patients, SeaStar Medical is poised to expand its impact across critical care, addressing a significant unmet need in both pediatric and adult populations.
What we're watching
- Clinical Validation
- Whether the continued positive data from the SAVE Registry will accelerate broader adoption of QUELIMMUNE in pediatric AKI treatment.
- Regulatory Pathway
- The pace at which SeaStar Medical can secure additional regulatory approvals for the SCD therapy in other indications.
- Market Expansion
- How the company will leverage its growing presence in the pediatric AKI community to expand into adult AKI and other critical care markets.
Related topics